Sector News

Roche taps Lilly executive Garraway as chief medical officer

August 20, 2019
Life sciences

Swiss drugmaker Roche Holding on Monday named Eli Lilly executive Levi Garraway to succeed Sandra Horning as chief medical officer and head of global product development.

Garraway, most recently Eli Lilly’s senior vice president, oncology research and development and Lilly research laboratories novel target research, will take up the post as of Oct. 1 and be based in South San Francisco.

Horning, who joined Roche and its Genentech division nearly a decade ago and has been chief medical officer since 2014, will retire as of the end of 2019, Roche said in a statement.

She led the product development organization, oversaw late-stage clinical development, and co-chaired the committee that invests in pivotal registrational trials.

Garraway joined Lilly in 2017 as senior vice president, global development and medical affairs for the oncology division. Before that he was director of the Joint Center for Cancer Precision Medicine, which spanned Harvard teaching hospitals.

In 2010, Garraway, a Harvard graduate, co-founded Foundation Medicine, which provides tumor molecular information.

By John Miller

Source: Reuters

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”